Contrast-associated acute kidney injury : does it really exist, and if so, what to do about it? by Vandenberghe, Wim & Hoste, Eric
 Open Peer Review
F1000 Faculty Reviews are commissioned from
members of the prestigious  . In orderF1000 Faculty
to make these reviews as comprehensive and
accessible as possible, peer review takes place
before publication; the reviewers are listed below,
but their reports are not formally published.
Any comments on the article can be found at the
end of the article.
REVIEW
Contrast-associated acute kidney injury: does it really exist, and
 if so, what to do about it? [version 1; peer review: 2 approved]
Wim Vandenberghe , Eric Hoste 1,2
Department of Intensive Care Medicine, University Hospital Ghent, Ghent University, C. Heymanslaan 10, 9000 Ghent, Belgium
Research Foundation-Flanders (FWO), Egmontstraat 5, 1000 Brussels, Belgium
Abstract
For decades, when contrast agents are administrated, physicians have
been concerned because of the risk of inducing acute kidney injury (AKI).
Recent literature questions the existence of AKI induced by contrast, but
animal studies clearly showed harmful effects. The occurrence of
contrast-associated AKI was likely overestimated in the past because of
confounders for AKI. Several strategies have been investigated to reduce
contrast-associated AKI but even for the most important one, hydration,
there are conflicting data. Even if the occurrence rate of contrast-associated
AKI is low, AKI is related to worse outcomes. Therefore, besides limiting
contrast agent usage, general AKI preventive measurements should be
applied in at-risk patients.
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Introduction
Iodinated radiocontrast agents are used for diagnostic 
radiography procedures as well as for therapeutic interventions. 
With the increasing use of non-invasive endovascular inter-
ventions, use of and exposure to contrast agents will further 
increase. Over decades, physicians were concerned about the 
harmful effects of contrast agents on kidney function. Recently, 
this fear led to doubts about whether contrast-associated acute 
kidney injury (CA-AKI) even exists and, if so, what is the 
clinical impact and are we able to prevent it?
Does contrast-associated acute kidney injury even 
exist?
Maybe the best illustration of the different opinions on the 
impact of contrast exposure on AKI is the use of many different 
terms. Classically, the term contrast-induced AKI was used; 
later, others suggested the terms CA-AKI and post-contrast 
AKI1,2. Contrast-induced AKI indicates a clear relationship 
between contrast administration and AKI. The latter two terms 
better illustrate the heterogeneity and multifactorial etiology of 
AKI in severely ill patients exposed to contrast agents. 
Post-contrast AKI emphasizes the temporal relationship between 
contrast exposure and AKI.
In experimental studies, it is clearly proven that contrast 
agents reduce renal blood flow in the medulla, induce free 
oxygen radicals, and induce apoptosis of renal tubular cells 
(Figure 1)3–5. Several trials have evaluated various strategies 
to prevent AKI after exposure to contrast agents. Even for the 
most accepted and most often used preventive measure, pre- 
hydration, there are conflicting data. Negative trials for 
preventive measures and conflicting data in controlled cohort 
studies may be an argument against a causative relationship 
between contrast agents and AKI6. Bias may occur in studies 
if the investigated preventive measure influences creatinine 
concentration even without effect on the contrast agent 
or its potential effects on kidney function. For example, 
N-acetylcysteine is associated with lower creatinine production, 
dialysis removes creatinine, and hydration can lead to dilution of 
creatinine7. On the other hand, in human studies, high-osmolar 
contrast agents were found to be harmful for kidneys and 
therefore are not used anymore8. The ultimate evidence on 
the toxicity of contrast administration would be a prospective 
randomized study in which patients who underwent, for exam-
ple, a computed tomography (CT) scan would be randomly 
assigned to a contrast-enhanced examination or standard. 
So far, such a study does not exist. Sophisticated statistical 
analyses may be used in cohort studies to account for differ-
ences in baseline characteristics and other confounders but 
these studies will always suffer from bias by unmeasured 
confounding.
Given that experimental data clearly demonstrate the toxic 
effects of contrast exposure on kidney function, we prefer to use 
the terminology CA-AKI throughout this article.
In severely ill patients with AKI, it is difficult to differentiate 
the role of contrast agents and other possible contributors to the 
Figure 1. Pathophysiology of contrast-associated acute kidney injury. CM, contrast media; GFR, glomerular filtration rate; NO, nitric 
oxide; ROS, reactive oxygen species; TGF, transforming growth factor. Modified version from Vandenberghe W, De Corte W, Hoste EA. 
Contrast-associated AKI in the critically ill: relevant or irrelevant? Current opinion in critical care. 2014 Dec;20(6):596-605. PubMed PMID: 
25314241. Epub 2014/10/159. By permission of Wolters Kluwer Health, Inc.
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development of AKI, such as hypotension, infection, inflamma-
tion, and other nephrotoxic medications10. To complicate things 
even more, even the procedure itself can have an influence on 
kidney function. During percutaneous coronary intervention 
(PCI), passage of the guidewire and catheter may disrupt plaques 
in the aorta, leading to micro-embolism and cholesterol emboli 
in the kidneys via the renal arteries11.
Another important issue is the definition used to diagnose 
CA-AKI. Chalikias et al.12 found that six different definitions 
were used in recent literature. Some used an absolute increase 
of serum creatinine which varied from at least 0.3 to at least 
1 mg/dL, and others used relative increases of 25 to 50% of 
baseline creatinine. Also, the duration of observation was 
different: classically a 48-hour follow-up time after contrast 
exposure and up to 6 days in the AMACING trial12,13. 
Chalikias et al. showed a wide variation of the occurrence rate 
of CA-AKI, between 1.3 and 15.8%, probably because of the 
use of different definitions together with differences in the 
patient cohort undergoing angiography12. We investigated the 
occurrence rate of CA-AKI in intensive care unit (ICU) patients 
after contrast administration for CT scan and non-coronary 
angiography and found that the occurrence rate of CA-AKI 
varied between 16.3 and 22.2% when CA-AKI was defined 
respectively as an increase of serum creatinine of 25 or 
0.5 mg/dL within 3 days or the Kidney Disease Improving 
Global Outcomes (KDIGO) classification for AKI1.
Is it possible to prevent contrast-associated acute 
kidney injury?
We should realize that there is important heterogeneity 
between patient groups exposed to contrast. Some groups 
are at greater risks than others and this also may explain the 
discussion on the relevance of CA-AKI. The risk for CA-AKI 
will be different in out-patients receiving contrast for coro-
nary angiography compared with ICU patients undergoing a 
contrast-enhanced CT scan. In patients who undergo coronary 
angiography, exposure to contrast is in most cases the single 
reason for AKI, whereas in critically ill patients who are having 
a contrast-enhanced CT scan, AKI is more likely the result of 
multiple hits. In fact, a contrast-enhanced CT scan is typically 
carried out in patients who are at greater risk for AKI. An 
illustrative example may be a patient with a suture leak one 
week after colectomy for colon cancer who develops septic 
shock. In this case, there are many risk factors besides contrast: 
previous major abdominal surgery, septic shock, and use of 
broad-spectrum antibiotics, including aminoglycosides and 
vancomycin. Here, simple preventive measures may make an 
important impact14,15.
Who should receive contrast prevention?
Especially in out-patients with normal kidney function 
undergoing elective procedures, the risk for CA-AKI and long-
term consequences is low. Preventive measures should be 
administered to patients at greatest risk for CA-AKI. Risk 
factors include decreased kidney function, as measured by 
an estimated glomerular filtration rate (eGFR) lower than 
45 mL/min per 1.73 m2, or the presence of other risk factors for 
AKI (Table 1).
Measures for contrast prevention
Several specific interventions to prevent CA-AKI have been 
investigated. We will discuss the use of hydration, bicarbonate, 
N-acetylcysteine, vitamins, statins, and dialysis.
Table 1. Risk factors for contrast-associated acute kidney injury2.
Risk factors for CA-AKI
Patient-related 
-   eGFR < 30 mL/min per 1.73 m2 before IV or IA CM administration                                         (level C) 
-   eGFR < 45 mL/min per 1.73 m2 if patient admitted on ICU or if IA CM administration            (level C) 
-   Risk factors for impaired renal function in general (not specific for CA-AKI)                           (level B) 
       ○    Old age 
       ○    Female gender 
       ○    Low body mass index 
       ○    Cardiovascular and metabolic risk factors 
       ○    Malignancy 
       ○    Inflammation 
       ○    Bleeding 
       ○    Anemia 
       ○    Hyperuricemia 
Procedure-related 
-   Repeated CM injections in a short period (48–72 hours)                                                              (level C) 
-   High CM dose                                                                                                                                (level C) 
       ○    Ratio of CM dose to absolute eGFR should be < 1.1 
       ○    Ratio of CM volume to eGFR should be < 3.0 (if CM concentration is 350 mg iodine/mL)
CA-AKI, contrast-associated acute kidney injury; CM, contrast media; eGFR, estimated glomerular filtration rate; IA,  
intra-arterial; ICU, intensive care unit; IV, intravenous.
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Hydration
Adequate hydration before and after contrast agent administra-
tion is regarded as the most important preventive strategy. Its 
rationale is that hydration leads to a lower concentration of 
contrast agent at the site of the renal tubules, which will reduce 
interaction of the contrast with the kidneys. Despite the wide 
adoption of hydration as a preventive measure for CA-AKI, 
this gets only level B evidence in the 2011 and 2018 guide-
lines for contrast medium–induced nephropathy by the contrast 
media safety committee of the European Society of Urogenital 
Radiology2,16,17. Recently, the AMACING trial, one of the few 
studies that actually compared hydration with no hydration, 
could not show a benefit for hydration as a preventive meas-
ure for CA-AKI13. In this study, patients who had an elective 
contrast-enhanced procedure and who had an eGFR lower than 
60 mL/min per 1.75 m2 but greater than 30 mL/min per 
1.75 m2, were prospectively included and allocated to a group 
with or without hydration13. The AMACING trial included 
patients with reduced kidney function for whom hydration as 
a preventive strategy is recommended. Interestingly, the inci-
dence of CA-AKI in this study cohort was less than 3% in both 
the intervention and control groups. Severely ill ICU patients who 
undeniably have a higher risk for the development of CA-AKI 
were excluded and therefore the results cannot be extrapolated to 
this population.
Hydration is also not without side effects and especially 
patients with reduced cardiac and kidney function are at risk of 
pulmonary edema. In this population, the volume of hydration 
is often reduced to prevent fluid overload, which of course may 
increase the risk of inadequate renal protection.
Hydration with bicarbonate or isotonic saline? Hydration 
with isotonic saline has been the standard for over a decade in 
coronary angiography18. Merten used bicarbonate as a scav-
enger for free reactive oxygen species in a solution with 
a concentration similar to that of NaCl 0.9% in order to 
protect kidneys against contrast19. Follow-up studies in which a 
bicarbonate regimen was compared with isotonic saline showed 
conflicting results; some studies and meta-analyses confirmed 
the benefits shown by the original study by Merten and others 
showed equal risk for CA-AKI. Unfortunately, most of these 
studies had important limitations in study design/conduct 
and most importantly were underpowered, limiting their 
interpretation2,20–23.
Recently, the adequately powered PRESERVE study, a prospec-
tive randomized study that had a 2 × 2 factorial design and that 
included 4993 patients with a high risk for renal complications 
after contrast administration, showed no benefit of intravenous 
sodium bicarbonate over intravenous sodium chloride for the 
prevention of death, need for dialysis, or persistent decline in 
kidney function at 90 days or for the prevention of CA-AKI24. 
The absence of benefit for sodium bicarbonate compared with 
isotonic saline was confirmed in a prospective multicenter 
randomized study in an ICU setting in patients with stable 
renal function25. Therefore, we should conclude that sodium 
bicarbonate solutions and isotonic saline are equally effective for 
prevention of CA-AKI in this type of patient.
Diuretics
Some preventive strategies such as the use of the osmotic 
diuretic mannitol or the loop diuretic furosemide are aimed 
at a reduction of exposure of the tubular cells to contrast by 
increasing tubular flow26. When increased urine production and 
negative fluid balance were not corrected, these strategies 
resulted in net fluid loss and so provided a nice model to show 
that volume depletion comes with increased risk for CA-AKI26. 
The RenalGuard System uses forced diuresis by means of 
furosemide in combination with a device that provides con-
tinuous intravenous fluid compensation of the urine produced27. 
This system prevented CA-AKI and fluid overload in three 
studies in patients who underwent coronary angiography or PCI 
with reduced cardiac function28,29.
N-acetylcysteine
Similar to sodium bicarbonate pre-hydration, N-acetylcysteine 
has been explored for prevention of CA-AKI for the supposed 
anti-oxidant effects on reactive oxygen species30. Since the 
original study by Tepel et al.30 in 2000, numerous studies and 
meta-analyses, most underpowered and with methodological 
flaws, have reported conflicting results on the use of N-acetyl-
cysteine for the prevention of CA-AKI. Recently, however, two 
large and adequately powered studies could show no benefit of 
N-acetylcysteine over placebo in different study cohorts. First, 
the ACT (Acetylcysteine for Contrast-Induced Nephropathy 
Trial), including 2308 patients in coronary angiography and 
peripheral vascular angiography, showed that at-risk patients 
exposed to high-dose N-acetylcysteine and placebo had similar 
rates of CA-AKI31. Also, the PRESERVE study (n = 4998) 
showed that the two groups had similar incidences of CA- 
AKI (N-acetylcysteine 9.1% versus placebo 8.7%, P = 0.58)24. 
In summary, the supposed preventive effect of N-acetylcysteine 
for CA-AKI could not be confirmed in several well-designed 
and adequately powered studies.
Statins
Statins have anti-oxidant, anti-inflammatory, and anti-thrombotic 
properties and restore renal nitric oxide (NO) production32. 
These mechanisms play a role in CA-AKI and therefore several 
trials have investigated various types and doses of statins as a 
preventive measure33. A meta-analysis containing 150 trials 
with several preventive strategies for CA-AKI found only a 
beneficial effect of statins on the general population34. In 2017, 
Liang et al. performed a meta-analysis of 15 randomized 
controlled trials (RCTs) about moderate- to high-dose rosuvas-
tatin for the prevention of CA-AKI after angiography or PCI35. 
A moderate to high dose of rosuvastatin, compared with low-
dose or no statin, reduced CA-AKI in that specific cohort35. 
In the same year, an RCT with atorvastatin confirmed the 
benefit for reducing CI-AKI36. Therefore, in patients undergo-
ing coronary angiography, an expert panel of the European 
Society of Intensive Care Medicine suggests the short-term use 
of atorvastatin or rosuvastatin to prevent CA-AKI37.
Renal replacement therapy
Hemodialysis is able to remove between 70 and 80% of the 
injected low-osmolar contrast media (LOCM) dose during a 4-hour 
session38–40. Although it is technically possible to remove a 
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certain amount of contrast dose, a 2012 meta-analysis by Cruz 
et al. showed insufficient evidence to support renal replacement 
therapy (RRT) to prevent CA-AKI41.
A potential explanation for the discrepancy between the ability 
to remove contrast by RRT and the lack of effect in preventing 
CA-AKI is that RRT induces inflammation, coagulation, and 
hypotension that in themselves may negatively affect kidney 
function41. Second, for practical reasons, there will inevi-
tably already be a considerable time of contrast exposure 
between time of administration and start of RRT. Probably, the 
nephrotoxic effects of contrast are most important immediately 
after administration when contrast concentration in the renal 
arteries and kidneys is highest41. Marenzi et al. randomized 
patients with severely impaired kidney function beforehand to 
initiation of hemofiltration before coronarography and 
continued afterwards and showed a less frequent rise in serum 
creatinine (which is not unexpected when RRT is used) and 
fewer complications in the intervention group compared to 
standard of care42. Limitations of this study, including 
unblinding and a higher level of care in the intervention arm 
compared with control patients, mean that this intervention 
cannot be recommended at present.
Vitamins C and E
Vitamins C and E have been evaluated as a preventive measure 
for CA-AKI for their anti-oxidant and scavenging effects. For 
vitamin C, encouraging results from cohort studies could not be 
confirmed in prospective studies43–45. Vitamin E was evaluated 
in four small prospective studies, and the individual studies 
and a meta-analysis (n = 623) showed that adding vitamin E to 
hydration regimens lowered the risk for CA-AKI46. These 
encouraging results should be confirmed in adequately powered 
studies before wide adoption of this preventive strategy can be 
recommended.
How can the radiologist or cardiologist make nice 
images without destruction of the kidneys?
Route of administration
The risk for CA-AKI seems lower when contrast media is 
administered intravenously rather than intra-arterially16. There 
are several explanations for this. During an intra-arterial contrast 
procedure, a higher dose is usually used and the transit time to 
the kidneys is shorter. The combination of these two factors will 
result in potentially higher concentrations of contrast medium 
in the kidneys. In addition, there are more procedure-related 
reasons for AKI. Advancing the catheter via the femoral artery 
to the aorta increases the risk for thrombo-emboly entering the 
renal arteries. The risk for CA-AKI is lower in coronary angi-
ography via the radial artery compared with the femoral 
approach47. This line of reasoning is merely theoretical since 
in clinical practice the route of administration—intravenous or 
intra-arterial—is procedure-related. Importantly, a higher risk 
for CA-AKI in patients with intra-arterial contrast may be 
explained by differences in baseline characteristics when com-
pared with patients who undergo intravenous contrast examina-
tion. Both Kooiman et al.48,49 and McDonald et al.48,49 addressed 
this potential bias by investigating paired cohorts of patients 
receiving both intra-arterial and intravenous contrast. The 
authors were not able to show a difference in occurrence rate 
of CA-AKI between intra-arterial versus intravenous contrast 
administration48,49.
Type of contrast medium
Contrast agents are categorized according to their osmolality 
as high-, iso-, or low-osmolar contrast media (HOCM, IOCM, 
and LOCM, respectively). Especially HOCM is a risk fac-
tor for CA-AKI and is not used anymore. Whether IOCM and 
LOCM agents have an advantage over each other is unclear. The 
Visipaque Angiography/Interventions with Laboratory Outcomes 
in Renal Insufficiency (VALOR) and Cardiac Angiography 
in Renally Impaired Patients (CARE) trials were not able to 
show a different in occurrence of CA-AKI when IOCM and 
LOCM were used in patients with chronic kidney disease under-
going angiography50,51. This was supported by a meta-analysis 
by Heinrich et al.52. Similar results were found recently in a meta-
analysis including prospectively randomized trials in diabetes 
patients, a high-risk group for CA-AKI53.
Volume of contrast agent
For every drug, too much is not good and will cause toxic-
ity. Similarly, increased volumes of administered contrast will 
lead to a higher occurrence rate of AKI. Laskey et al. related 
volume of contrast to kidney function and found that a contrast 
volume equal to 3.7 times creatinine clearance was associated 
with an early abnormal increase in serum creatinine in patients 
undergoing PCI54. This finding also nicely illustrates that patients 
may have different risk profiles. Patients with normal kidney 
function have a very low risk for CA-AKI whereas patients 
with decreased kidney function are at greater risk. A safe 
dose does not exist, and it is prudent to always use the smallest 
amount of contrast agent necessary to perform the investigation16.
Use of other imaging techniques: magnetic resonance 
imaging and gadolinium and carbon dioxide
Magnetic resonance imaging (MRI) could be an alternative for 
imaging in certain situations. Of course, a major disadvantage 
of MRI is the limited availability of this procedure. Also, early 
experience showed that gadolinium-based contrast agents 
(GBCAs) are associated with a decline in kidney function and 
evolution to nephrogenic systemic fibrosis (NSF). In 2017, 
Scharnweber et al. investigated the use of GBCA in patients with 
AKI, severe chronic kidney insufficiency, or even kidney failure 
with or without dialysis55. Currently, according to their findings, 
macrocyclic agents and the newer linear agents (“cyclic” and 
“linear” are both chemical structures of GBCA) have a low 
risk of causing NSF when administered in a routine dose 
and when repeated injections are avoided55.
In clinical practice, it is probably very seldom that a physician 
chooses MRI above CT solely for kidney-protective reasons 
and this is because of limited availability and the potential nega-
tive effects of MRI GBCAs on kidney function, especially in 
patients with chronic kidney disease. Carbon dioxide (CO2) is 
inexpensive and can be used in certain procedures as an alternative 
to iodinated contrast agents when MRI and gadolinium are used56.
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What if, after all preventive measurements, contrast-
associated acute kidney injury still occurs?
We found that in ICU patients CA-AKI was associated with 
longer length of stay, worse survival in hospital, and a higher 
mortality up to 1 year after contrast administration1. When we 
reviewed literature for outcome after CA-AKI in different patient 
cohorts, we found conflicting results for mortality. We found that 
there was a greater risk for increased mortality in observational 
studies compared with a similar risk with or without contrast 
agent in matched case control studies9. Difference in baseline 
characteristics probably plays an important role here. In 
clinical practice, we are less likely to order a contrast-enhanced 
CT scan in patients at greater risk for CA-AKI. Therefore, the 
patients we deny contrast, because of a high risk for AKI, will 
be categorized in the control group.
If AKI occurs after the administration of contrast, the same rec-
ommendations formulated by the KDIGO in preventing AKI 
can be used: evaluate whether it is possible to stop nephrotoxic 
agents such as aminoglycosides, vancomycin, non-steroidal 
anti-inflammatory drugs, angiotensin-converting enzyme inhibi-
tor, and angiotensin receptor blocker; optimize hemodynamics 
and volume status; closely monitor kidney function and fluid 
balance; avoid hyperglycemia; avoid further exposure to 
contrast agents; and avoid gelatins, colloids, and chloride-rich 
solutions14,15.
Conclusions
Contrast media will harm the kidneys through several patho-
physiological mechanisms. However, the true impact of contrast 
administration on the occurrence of AKI is a matter of debate. 
AKI after contrast administration has a very low occurrence 
rate in low-risk patients and is frequent in critically ill at-risk 
patients. In this last group, other mechanisms may also play a 
role in the development of AKI. Therefore, the term CA-AKI is 
preferred. CA-AKI is associated with worse outcomes. Avoid-
ing or minimizing the volume of contrast media is recom-
mended, and general preventive measurements for AKI should 
be applied in patients with risk factors. Pre-hydration is the 
preferred preventive measure that should be used in patients 
with risk factors for the development of CA-AKI. In coronary 
angiography, a high dose of statins has been shown to diminish 
the risk for CA-AKI.
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